Results 271 to 280 of about 49,135 (301)

Dabigatran as an oral anticoagulant in patients with Budd–Chiari syndrome post‐percutaneous endovascular intervention

Journal of Gastroenterology and Hepatology, 2020
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma, Ramesh Kumar, Gyanranjan Rout, S. Gamanagatti, R. Shalimar   +4 more
semanticscholar   +1 more source

Dabigatran, bleeding, and the regulators

BMJ, 2014
Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of ...
Thomas J, Moore, Michael R, Cohen, Donald R, Mattison   +2 more
openaire   +2 more sources

Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke

Stroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous ...
J. Beharry, M. Waters, R. Drew, J. Fink, D. Wilson, B. Campbell, M. Parsons, T. Kleinig, Teddy Y. Wu   +8 more
semanticscholar   +1 more source

Dabigatran: A Primer for Neurosurgeons

World Neurosurgery, 2013
This study sought to present an overview of dabigatran, a new anticoagulant, and to discuss the implications for the perioperative management of patients taking dabigatran.We reviewed the English literature pertaining to the new oral anticoagulant, dabigatran (Pradaxa).Dabigatran has the advantage of providing rapid and steady anticoagulation without ...
Jennifer E, Fugate, Alejandro A, Rabinstein, Robert D, McBane, Giuseppe, Lanzino   +3 more
openaire   +2 more sources

Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease

Drug Metabolism and Personalized Therapy, 2020
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev, A. Skripka, Kristina Ryzhikova, P. Bochkov, R. Shevchenko, P. Krupenin, D. Ivashchenko, V. Kogay, A. Listratov, A. Krainyaya, O. Gurinovich, A. Sokolova, D. Napalkov, V. Fomin   +13 more
semanticscholar   +1 more source

Removal of Dabigatran by Hemodialysis

American Journal of Kidney Diseases, 2013
Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
Don N, Chang, William E, Dager, Andrew I, Chin   +2 more
openaire   +2 more sources

Use of dabigatran with antiretrovirals

HIV Medicine, 2019
ObjectivesTheoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral ...
J Perram, E O'Dwyer, C Holloway
openaire   +2 more sources

Reversal of Dabigatran with Idarucizumab

Expert Review of Cardiovascular Therapy, 2016
The use of novel oral anticoagulants such as dabigatran has been increasing over the last five years. Indicated for use in the prevention of thromboembolic complications from non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolic disease, dabigatran is increasingly encountered clinically.
Neel R, Sodha, Frank W, Sellke
openaire   +2 more sources

Dabigatran in Clinical Practice

Clinical Therapeutics, 2012
Stroke and systemic thromboembolism remain critical causes of mortality and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate is a novel oral direct thrombin inhibitor, which provides stroke risk reduction for patients with nonvalvular atrial fibrillation. Randomized clinical data demonstrate dabigatran to be
Rangadham, Nagarakanti, Christopher R, Ellis   +1 more
openaire   +2 more sources

Pros and cons of dabigatran

American Journal of Health-System Pharmacy, 2011
As described in this issue of AJHP (see page 1506), dabigatran etexilate is the first oral direct thrombin inhibitor and the first oral anticoagulant since warfarin to become available in the United States.
Christine M, Cheng, Megan R, McCurdy, Heather A, Wong, Steven R, Kayser   +3 more
openaire   +2 more sources